Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.
2.

Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163.

Standl E, Green JB, Holman RR; TECOS Study Group.

Diabetes Care. 2019 Jun;42(6):e95. doi: 10.2337/dc18-2597. No abstract available.

PMID:
31110121
3.

Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85).

Maddaloni E, Coleman RL, Pozzilli P, Holman RR.

Diabetes Obes Metab. 2019 May 17. doi: 10.1111/dom.13788. [Epub ahead of print]

PMID:
31099472
4.

Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes.

Guimarães PO, Peterson ED, Stevens SR, Lokhnygina Y, Green JB, McGuire DK, Holman RR, Lopes RD.

Int J Cardiol. 2019 Aug 15;289:58-62. doi: 10.1016/j.ijcard.2019.04.085. Epub 2019 Apr 30.

PMID:
31079973
5.

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL).

Bethel MA, Patel RA, Thompson VP, Merrill P, Reed SD, Li Y, Ahmadi S, Katona BG, Gustavson SM, Ohman P, Iqbal N, Gagel RF, Hernandez AF, Buse JB, Holman RR; EXSCEL Study Group.

Diabetes Care. 2019 Jun;42(6):1075-1080. doi: 10.2337/dc18-2028. Epub 2019 Apr 22.

PMID:
31010875
6.

An outcome model approach to transporting a randomized controlled trial results to a target population.

Goldstein BA, Phelan M, Pagidipati NJ, Holman RR, Pencina MJ, Stuart EA.

J Am Med Inform Assoc. 2019 May 1;26(5):429-437. doi: 10.1093/jamia/ocy188.

PMID:
30869798
7.

Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010-2017.

Dennis JM, Henley WE, McGovern AP, Farmer AJ, Sattar N, Holman RR, Pearson ER, Hattersley AT, Shields BM, Jones AG; MASTERMIND consortium.

Diabetes Obes Metab. 2019 Jul;21(7):1576-1584. doi: 10.1111/dom.13687. Epub 2019 Apr 4.

PMID:
30828962
8.

Progression of glucose-lowering diabetes therapy in TECOS.

Bethel MA, Engel SS, Stevens SR, Lokhnygina Y, Ding J, Josse RG, Alvarsson M, Hramiak I, Green JB, Peterson ED, Holman RR; TECOS Study Group.

Endocrinol Diabetes Metab. 2018 Dec 22;2(1):e00053. doi: 10.1002/edm2.53. eCollection 2019 Jan.

9.

Real-world studies no substitute for RCTs in establishing efficacy.

Gerstein HC, McMurray J, Holman RR.

Lancet. 2019 Jan 19;393(10168):210-211. doi: 10.1016/S0140-6736(18)32840-X. No abstract available.

PMID:
30663582
10.

Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials.

Fanaroff AC, Clare R, Pieper KS, Mahaffey KW, Melloni C, Green JB, Alexander JH, Jones WS, Harrison RW, Mehta RH, Povsic TJ, Moreira HG, Al-Khatib SM, Roe MT, Kong DF, Mathews R, Tricoci P, Holman RR, Wallentin L, Held C, Califf RM, Alexander KP, Lopes RD.

Circulation. 2019 Feb 12;139(7):863-873. doi: 10.1161/CIRCULATIONAHA.118.037202.

PMID:
30586739
11.

Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.

Mentz RJ, Thompson VP, Aguilar D, Choi J, Gustavson SM, Iqbal N, Kong AP, Öhman P, Sattar N, Scott RS, Wong YW, Holman RR, Hernandez AF.

Circulation. 2018 Nov 27;138(22):2576-2578. doi: 10.1161/CIRCULATIONAHA.118.036811. No abstract available.

PMID:
30571356
12.

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.

Clegg LE, Heerspink HJL, Penland RC, Tang W, Boulton DW, Bachina S, Fox RD, Fenici P, Thuresson M, Mentz RJ, Hernandez AF, Holman RR.

Diabetes Care. 2019 Feb;42(2):318-326. doi: 10.2337/dc18-1871. Epub 2018 Dec 6.

PMID:
30523029
13.

Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCEL Trial.

Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, Felício JS, Goodman SG, Choi J, Gustavson SM, Iqbal N, Lopes RD, Maggioni AP, Öhman P, Pagidipati NJ, Poulter NR, Ramachandran A, Reicher B, Holman RR, Hernandez AF; EXSCEL Study Group.

J Am Heart Assoc. 2018 Oct 2;7(19):e009304. doi: 10.1161/JAHA.118.009304.

14.

Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates.

Mostafa SA, Coleman RL, Agbaje OF, Gray AM, Holman RR, Bethel MA.

J Diabetes Complications. 2019 Jan;33(1):69-74. doi: 10.1016/j.jdiacomp.2018.09.017. Epub 2018 Oct 10.

PMID:
30361000
15.

Relationship between baseline physical activity assessed by pedometer count and new-onset diabetes in the NAVIGATOR trial.

Kraus WE, Yates T, Tuomilehto J, Sun JL, Thomas L, McMurray JJV, Bethel MA, Holman RR.

BMJ Open Diabetes Res Care. 2018 Jul 19;6(1):e000523. doi: 10.1136/bmjdrc-2018-000523. eCollection 2018.

16.

Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.

Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT; MASTERMIND Consortium.

Diabetes Care. 2018 Sep;41(9):1844-1853. doi: 10.2337/dc18-0344. Epub 2018 Aug 2.

17.

Comparison of nine platelet function tests used to determine responses to different aspirin dosages in people with type 2 diabetes.

Harrison P, Bethel MA, Kennedy I, Dinsdale R, Coleman R, Holman RR.

Platelets. 2019;30(4):521-529. doi: 10.1080/09537104.2018.1478402. Epub 2018 Jul 9.

PMID:
29985735
18.

Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.

Alfredsson J, Green JB, Stevens SR, Reed SD, Armstrong PW, Angelyn Bethel M, Engel SS, McGuire DK, Van de Werf F, Hramiak I, White HD, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2018 Oct;20(10):2379-2388. doi: 10.1111/dom.13377. Epub 2018 Jun 19.

PMID:
29923323
19.

Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis.

Lim LL, Lau ESH, Kong APS, Davies MJ, Levitt NS, Eliasson B, Aguilar-Salinas CA, Ning G, Seino Y, So WY, McGill M, Ogle GD, Orchard TJ, Clarke P, Holman RR, Gregg EW, Gagliardino JJ, Chan JCN.

Diabetes Care. 2018 Jun;41(6):1312-1320. doi: 10.2337/dc17-2010. Review.

20.

A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks.

Riddle MC, Gerstein HC, Holman RR, Inzucchi SE, Zinman B, Zoungas S, Cefalu WT.

Diabetes Care. 2018 Jun;41(6):1121-1124. doi: 10.2337/dci18-0018. No abstract available.

PMID:
29784695
21.

What does the Acarbose Cardiovascular Evaluation (ACE) trial tell us?

Holman RR.

J Diabetes. 2018 Aug;10(8):683-685. doi: 10.1111/1753-0407.12770. Epub 2018 May 17. No abstract available.

PMID:
29774661
22.

Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.

Theodorakis MJ, Coleman RL, Feng H, Chan J, Chiasson JL, Ge J, Gerstein HC, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Tendera M, Tuomilehto J, Yang W, Hu D, Pan C, Holman RR; ACE Study Group.

Am Heart J. 2018 May;199:170-175. doi: 10.1016/j.ahj.2017.09.001. Epub 2017 Sep 8. No abstract available.

PMID:
29754657
23.

Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT.

Griffin SJ, Bethel MA, Holman RR, Khunti K, Wareham N, Brierley G, Davies M, Dymond A, Eichenberger R, Evans P, Gray A, Greaves C, Harrington K, Hitman G, Irving G, Lessels S, Millward A, Petrie JR, Rutter M, Sampson M, Sattar N, Sharp S.

Health Technol Assess. 2018 Apr;22(18):1-64. doi: 10.3310/hta22180.

24.

Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Reed SD, Li Y, Leal J, Radican L, Adler AI, Alfredsson J, Buse JB, Green JB, Kaufman KD, Riefflin A, Van de Werf F, Peterson ED, Gray AM, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2018 Jul;20(7):1732-1739. doi: 10.1111/dom.13292. Epub 2018 Apr 20.

PMID:
29573215
25.

Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Davis TME, Mulder H, Lokhnygina Y, Aschner P, Chuang LM, Raffo Grado CA, Standl E, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2018 Jun;20(6):1427-1434. doi: 10.1111/dom.13242. Epub 2018 Feb 28.

PMID:
29405540
26.

Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy.

Dennis JM, Shields BM, Hill AV, Knight BA, McDonald TJ, Rodgers LR, Weedon MN, Henley WE, Sattar N, Holman RR, Pearson ER, Hattersley AT, Jones AG; MASTERMIND Consortium.

Diabetes Care. 2018 Apr;41(4):705-712. doi: 10.2337/dc17-1827. Epub 2018 Jan 31.

27.

Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.

Standl E, Stevens SR, Armstrong PW, Buse JB, Chan JCN, Green JB, Lachin JM, Scheen A, Travert F, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2018 Mar;41(3):596-603. doi: 10.2337/dc17-1778. Epub 2018 Jan 8.

PMID:
29311155
28.

Management of T2DM in 2017: Clinically relevant results from cardiovascular outcome trials.

Holman RR.

Nat Rev Endocrinol. 2018 Feb;14(2):67-68. doi: 10.1038/nrendo.2017.179. Epub 2018 Jan 5. Review. No abstract available.

PMID:
29302077
29.

Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum.

Cefalu WT, Kaul S, Gerstein HC, Holman RR, Zinman B, Skyler JS, Green JB, Buse JB, Inzucchi SE, Leiter LA, Raz I, Rosenstock J, Riddle MC.

Diabetes Care. 2018 Jan;41(1):14-31. doi: 10.2337/dci17-0057.

30.

Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.

Holman RR, Bethel MA, Hernandez AF.

N Engl J Med. 2017 Dec 21;377(25):2502. doi: 10.1056/NEJMc1714163. No abstract available.

PMID:
29262286
31.

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group.

Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6. Epub 2017 Dec 6.

32.

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease.

Mostafa SA, Coleman RL, Agbaje OF, Gray AM, Holman RR, Bethel MA.

Diabet Med. 2018 Jan;35(1):72-77. doi: 10.1111/dme.13533. Epub 2017 Nov 16.

PMID:
29057545
33.

Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.

Sharma A, Green JB, Dunning A, Lokhnygina Y, Al-Khatib SM, Lopes RD, Buse JB, Lachin JM, Van de Werf F, Armstrong PW, Kaufman KD, Standl E, Chan JCN, Distiller LA, Scott R, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2017 Dec;40(12):1763-1770. doi: 10.2337/dc17-1091. Epub 2017 Oct 6.

PMID:
28986504
34.

Health selection into neighborhoods among patients enrolled in a clinical trial.

Arcaya MC, Coleman RL, Razak F, Alva ML, Holman RR.

Prev Med Rep. 2017 Jul 24;8:51-54. doi: 10.1016/j.pmedr.2017.07.003. eCollection 2017 Dec.

35.

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C; ACE Study Group.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13. Erratum in: Lancet Diabetes Endocrinol. 2017 Nov;5(11):e7. Lancet Diabetes Endocrinol. 2019 May;7(5):e5.

PMID:
28917545
36.

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group.

N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.

37.

Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis.

Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, Odden MC, Peralta CA, Cheung AK, Nadkarni GN, Coleman RL, Holman RR, Zanchetti A, Peters R, Beckett N, Staessen JA, Ix JH.

JAMA Intern Med. 2017 Oct 1;177(10):1498-1505. doi: 10.1001/jamainternmed.2017.4377. Review.

38.

Hypertension Control in Adults With Diabetes Mellitus and Recurrent Cardiovascular Events: Global Results From the Trial Evaluating Cardiovascular Outcomes With Sitagliptin.

Navar AM, Gallup DS, Lokhnygina Y, Green JB, McGuire DK, Armstrong PW, Buse JB, Engel SS, Lachin JM, Standl E, Van de Werf F, Holman RR, Peterson ED; TECOS Study Group.

Hypertension. 2017 Nov;70(5):907-914. doi: 10.1161/HYPERTENSIONAHA.117.09482. Epub 2017 Aug 28.

39.

Continuous glucose monitoring detected hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T).

Levy JC, Davies MJ, Holman RR; 4-T Study Group.

Diabetes Res Clin Pract. 2017 Sep;131:161-168. doi: 10.1016/j.diabres.2017.01.022. Epub 2017 Mar 21.

PMID:
28750219
40.

Microvascular outcomes in type 2 diabetes - Authors' reply.

Zoungas S, Gerstein HC, Holman RR, Reaven P, Woodward M, Arima H, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) writing group.

Lancet Diabetes Endocrinol. 2017 Aug;5(8):580. doi: 10.1016/S2213-8587(17)30185-7. No abstract available.

PMID:
28732664
41.

Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis.

Oulhaj A, El Ghouch A, Holman RR.

Stat Methods Med Res. 2019 Jan;28(1):151-169. doi: 10.1177/0962280217717761. Epub 2017 Jul 3.

PMID:
28670972
42.

Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).

Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED; TECOS Study Group.

Circulation. 2017 Sep 26;136(13):1193-1203. doi: 10.1161/CIRCULATIONAHA.117.027252. Epub 2017 Jun 16.

43.

Do glycoalbumin levels preferentially reflect changes in postprandial glucose excursions?

Paul SK, Holman RR.

Diabet Med. 2017 Sep;34(9):1284-1290. doi: 10.1111/dme.13376. Epub 2017 Jun 13.

PMID:
28477414
45.

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Mentz RJ, Bethel MA, Gustavson S, Thompson VP, Pagidipati NJ, Buse JB, Chan JC, Iqbal N, Maggioni AP, Marso SP, Ohman P, Poulter N, Ramachandran A, Zinman B, Hernandez AF, Holman RR.

Am Heart J. 2017 May;187:1-9. doi: 10.1016/j.ahj.2017.02.005. Epub 2017 Feb 12.

PMID:
28454792
46.

Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.

Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2017 Nov;19(11):1587-1593. doi: 10.1111/dom.12983. Epub 2017 Jul 7.

PMID:
28432745
47.

Corrections needed to 2016 ESC and AHA guidelines on heart failure.

Rydén L, Van de Werf F, Armstrong PW, McGuire DK, Standl E, Peterson ED, Holman RR.

Lancet Diabetes Endocrinol. 2017 May;5(5):325-326. doi: 10.1016/S2213-8587(17)30102-X. Epub 2017 Apr 5. No abstract available. Erratum in: Lancet Diabetes Endocrinol. 2017 Jun;5(6):e4.

PMID:
28395875
48.

Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.

Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, Hayward RA, Craven T, Coleman RL, Chalmers J; Collaborators on Trials of Lowering Glucose (CONTROL) group.

Lancet Diabetes Endocrinol. 2017 Jun;5(6):431-437. doi: 10.1016/S2213-8587(17)30104-3. Epub 2017 Mar 30.

PMID:
28365411
49.

Updated risk factors should be used to predict development of diabetes.

Bethel MA, Hyland KA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, Jenssen T, Levitt NS, McMurray JJV, Boutati E, Thomas L, Sun JL, Haffner SM; NAVIGATOR Study Group.

J Diabetes Complications. 2017 May;31(5):859-863. doi: 10.1016/j.jdiacomp.2017.02.012. Epub 2017 Mar 2.

PMID:
28319004
50.

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.

Currie G, Bethel MA, Holzhauer B, Haffner SM, Holman RR, McMurray JJV.

Diabetes Obes Metab. 2017 Jun;19(6):791-799. doi: 10.1111/dom.12877. Epub 2017 Mar 17.

PMID:
28093841

Supplemental Content

Loading ...
Support Center